

National implementation of EUnetHTA assessments

EUnetHTA MedTech Technical Meeting


27th May 2019 - Vienna

Methods

- Implementation data are collected for all published assessments.
- Implementation feedback survey is sent out after publication of each assessment
- Respondents can revise / update responses if status changes.
- Survey includes categories to measure type of use and also factors that limit or prevent use (WP1 metric tool).
- Data are downloaded, 'cleaned' and analysed every 2 to 3 months.
- Implementation data are included in WP7 implementation reports published bi-annually (<https://www.eunetha.eu/national-implementation/implementation-reports>).
- Selected survey responses are followed up with semi-structured interviews to explore survey findings in detail




Number of uses of JA3 assessments




★ Less than 1 year since publication

Comparison – JA3 and JA2

- With further follow up use of other technologies (OT) assessments is likely to be comparable under JA3 (orange) with JA2 (blue).



Countries reporting use of other technologies assessments




- 19 countries report using at least one JA3 OT assessment (up from 9 in May 2018).
- Red denotes use in assessment, yellow is dissemination only.

Data: April 2019

Type of use of JA3 other technologies assessments

- Most agencies add additional information
- Compared with pharmaceuticals more agencies are able to use the assessments with either no changes or translation only




Non-use of other technologies assessments

- Higher levels of non-use (defined as agencies working in the topic area and not using the EUnetHTA assessment) for other technologies than for pharmaceuticals

	Worked on the topic but did not use the EUnetHTA assessment
OTCA01 (Wearable cardioverter-defibrillator)	4
OTCA02 (Antibacterial-coated Sutures)	2
OTCA03 (NIPT)	11
OTCA04 (MammaPrint)	6
OTCA05 (Magnetic stimulation)	7
OTCA06 (TAVI)	2
OTCA07 (FLACS)	1
OTJA08 (Glucose Monitoring)	8
OTCA09 (HIFU Ablation)	8
OTCA12 (CRP POCT)	2
OTCA16 (Stents)	1
Total	52

Reasons for non-use of other technologies assessments



- awareness
- Reliability
- Language
- Timing
- Relevance
- Reporting structure
- Evidence and methodology
- Transferability
- Accountability

Data: April 2019

Summary

- 11 assessments of other technologies published in JA3
- Positive indicators:
 - 103 examples of use, 46 in assessment procedures and 57 in dissemination activities.
 - It is expected that with longer follow up use will be comparable with JA2.
 - Number of countries using OT assessments is increasing
 - In general, agencies assessing OT use reports more efficiently than pharmaceutical assessments and more frequently replace agency work
- Different set of challenges to uptake of pharmaceutical assessments
 - Key issues to address – topic alignment with agency priorities, timing to carry out the assessments, maximising relevance given range of decisions HTA of other technologies may inform

Questions

